GlassScriptPhysician profile
Natalie Tafel
NPI 1760537229
$76,643.59
in general payments reported to CMS, 2019-2025
26 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,575 · 2022: $4,129 · 2023: $13K · 2024: $29K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $14K · Consulting Fee: $7,433 · Food and Beverage: $4,434 · Honoraria: $3,492 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,469 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,255.50 |
| Travel and Lodging | $13,795.72 |
| Consulting Fee | $7,433.00 |
| Food and Beverage | $4,434.25 |
| Honoraria | $3,492.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,468.75 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33,090.46 | 2021-2025 | Iclusig, Ninlaro |
| Rigel Pharmaceuticals, INC. | $30,209.29 | 2022-2025 | Rezlidhia, Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $8,138.45 | 2023-2025 | |
| Amgen INC. | $2,187.46 | 2025 | Blincyto |
| Novartis Pharmaceuticals Corporation | $594.64 | 2021-2025 | |
| Geron Corporation | $512.50 | 2025 | Rytelo |
| Sobi, INC | $387.79 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $301.10 | 2024-2025 | Ultomiris |
| Incyte Corporation | $250.00 | 2021-2023 | Jakafi |
| Glaxosmithkline, LLC. | $191.59 | 2023-2025 | Ojjaara |
| Daiichi Sankyo INC. | $162.43 | 2023-2025 | Vanflyta |
| Jazz Pharmaceuticals INC. | $100.92 | 2022-2024 | |
| Pfizer INC. | $96.18 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $60.82 | 2025 | Danziten |
| Astellas Pharma US INC | $55.96 | 2025 | Cresemba |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $48.53 | 2022 | |
| Celgene Corporation | $37.41 | 2025 | Reblozyl |
| Genentech USA, INC. | $34.11 | 2023-2024 | Venclexta |
| Merck Sharp & Dohme LLC | $27.07 | 2023 | |
| Blueprint Medicines Corporation | $26.03 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $25.08 | 2023 | |
| Stemline Therapeutics INC. | $24.55 | 2025 | Elzonris |
| Genzyme Corporation | $22.08 | 2023 | |
| Abbvie INC. | $21.53 | 2021 | |
| Pharmaessentia USA Corporation | $20.58 | 2023 | Besremi |
| Cti Biopharma Corp. | $17.03 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Tafel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.